Free Trial
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics logo
$1.37 +0.03 (+2.54%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Galectin Therapeutics Stock (NASDAQ:GALT)

Key Stats

Today's Range
$1.33
$1.40
50-Day Range
$1.22
$1.77
52-Week Range
$0.73
$3.78
Volume
29,779 shs
Average Volume
316,558 shs
Market Capitalization
$86.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Hold

Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

GALT MarketRank™: 

Galectin Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 825th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Galectin Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galectin Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galectin Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Galectin Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.09% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 28.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving.
  • Dividend Yield

    Galectin Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galectin Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.09% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 28.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving.
  • MarketBeat Follows

    3 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

  • Read more about Galectin Therapeutics' insider trading history.
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Stock News Headlines

The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
Galectin Therapeutics reports FY24 EPS (76c) vs (74c) last year
Galectin Therapeutics’ belapectin shows reduction in new varices
See More Headlines

GALT Stock Analysis - Frequently Asked Questions

Galectin Therapeutics' stock was trading at $1.29 at the beginning of 2025. Since then, GALT shares have increased by 7.4% and is now trading at $1.3860.
View the best growth stocks for 2025 here
.

Galectin Therapeutics Inc. (NASDAQ:GALT) issued its earnings results on Monday, March, 31st. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.03.

Galectin Therapeutics' top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.06%) and FNY Investment Advisers LLC. Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin and Jack W Callicutt.
View institutional ownership trends
.

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
3/31/2025
Today
4/24/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GALT
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+697.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.01) per share
Price / Book
-1.37

Miscellaneous

Free Float
31,318,000
Market Cap
$87.19 million
Optionable
Optionable
Beta
0.79

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:GALT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners